The Lancet Infectious Diseases in conversation with
The Lancet Group
18 episodes
2 weeks ago
Professors Steven Tong and Joshua Davis discuss all aspects of adaptive platform trials including advantages, disadvantages, differences from conventional trials, and tips for setting up and assessing them. They also highlight several adaptive platform trials currently in the pipeline that could influence infectious disease clinical practise in the future. Click here to read our latest issue Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://ins...
All content for The Lancet Infectious Diseases in conversation with is the property of The Lancet Group and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Professors Steven Tong and Joshua Davis discuss all aspects of adaptive platform trials including advantages, disadvantages, differences from conventional trials, and tips for setting up and assessing them. They also highlight several adaptive platform trials currently in the pipeline that could influence infectious disease clinical practise in the future. Click here to read our latest issue Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://ins...
Luciano Moreira and Henrik Salje on Wolbachia control of mosquito-borne infections
The Lancet Infectious Diseases in conversation with
17 minutes
3 years ago
Luciano Moreira and Henrik Salje on Wolbachia control of mosquito-borne infections
Luciano Moreira and Henrik Salje discuss a new article in The Lancet Infectious Diseases describing the use of the Wolbachia bacteria to control the spread of mosquito-borne dengue and chikungunya in Rio de Janeiro, Brazil.Read the full article:Estimating the effect of the wMel release programme on the incidence of dengue and chikungunya in Rio de Janeiro, BrazilContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://f...
The Lancet Infectious Diseases in conversation with
Professors Steven Tong and Joshua Davis discuss all aspects of adaptive platform trials including advantages, disadvantages, differences from conventional trials, and tips for setting up and assessing them. They also highlight several adaptive platform trials currently in the pipeline that could influence infectious disease clinical practise in the future. Click here to read our latest issue Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://ins...
